EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.

Medicine (Baltimore) · 2016 · PMC5268044 · PMID 27977598

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In summary, there was only a nonsignificant trend toward improved OS for the EGFR-TKIs over taxanes groups (HR = 1.00, 95% CI: 0.95–1.05).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.